博拓生物(688767.SH):傳染病檢測系列包含針對基孔肯雅熱等熱帶傳染病的檢測試劑
格隆匯8月1日丨博拓生物(688767.SH)在互動平台表示,公司傳染病檢測系列包含針對基孔肯雅熱等熱帶傳染病的檢測試劑。該產品在境外部分市場可以進行銷售,未對公司當前收入及利潤產生重大影響。國內市場尚未取得基孔肯雅熱相關醫療器械註冊證,目前僅作為科研試劑適用於海關、疾控等應用場景的檢測需求。公司在國內已取得蚊媒類傳染病註冊證書的產品有登革抗原檢測試劑(膠體金法)、惡性瘧原蟲富組氨酸蛋白Ⅱ(HRP-Ⅱ)抗原檢測試劑(膠體金法)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.